We have a once-in-a-generation opportunity to make medicines affordable for our patients and support the health needs of every family in our nation. As physicians, now is the time to elevate the voices of our patients and act. Congress is currently working to finalize the provisions included in the […]
Latest Stories
Opinion: The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars
First Opinion The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars By Dan Leonard Nov. 6, 2021 Reprints Adobe A mericans rightfully expect Congress to address the ever-increasing prices of brand-name prescription drugs. Read the […]
Takeda Partners With Point32Health to Offer Value-Based Oncology Program in US
Takeda has partnered with Point32Health in a new value-based oncology program. Alunbrig, used in non-small cell lung cancer, is the first drug offered through the pilot project; if successful, Takeda promises to expand the program. Takeda Oncology’s Dion Warren remarks, “We need to learn through […]
Roche Turns to RWE in Lung Cancer Study
Roche turned to real world evidence (RWE) to understand how a subgroup of patients with an anaplastic lymphoma kinase translocation (ALK) who were diagnosed with non-small cell lung cancer (NSCLC) responded to the drug alectinib. The use of RWE sped up research into the drug and led to regulatory […]
Japan Generic Drugs Market to Establish Growth with Impressive CAGR by 2027 | TechSci
Japan Generic Drugs Market to Establish Growth with Impressive CAGR by 2027 | TechSci [Shipra J.] Market Research for Better Business Growth Enhancing pharmaceutical sector in the country is driving the growth if Japan Generic drugs Market, FY2017-FY2027. Read the source article at Business […]
The Cancer Supportive Care Products Market To Stick To The Innovative Invigoration
The global Cancer Supportive Care Products Market is there to witness an irrevocable In Upcoming Years. Innovation in the form of digital tools is the buzzword all across. Even though it’s the youth engaging in digital and social platforms, the geriatric population could get benefited by engaging […]
Democrats’ drug pricing deal is ‘not a bad outcome’ for pharma, analysts write
Democrats' drug pricing deal is 'not a bad outcome' for pharma, analysts write esagonowsky Fri, 11/05/2021 - 11:14 Read the source article at Pharma News 2021-11-05 16:14:41 […]
Amgen plays multi-specific matchmaker in quest to tackle the undruggable
Amgen plays multi-specific matchmaker in quest to tackle the undruggable aarmstrong Thu, 11/04/2021 - 10:27 Read the source article at fiercebiotech.com 2021-11-04 15:27:55 […]
Merck’s Keytruda Expected to Hit $17 Billion Yearly Revenue
Merck’s Keytruda continues to generate billion-dollar sales. The oncology drug reached $4.5 billion of sales in the third quarter, making a cornerstone of Merck’s offerings. Its list price is approximately $175,000 per year. “Keytruda is close to becoming the highest-selling drug in the world and […]
[Podcast] Understanding the Limitations of Proposed Drug Pricing Reforms
Terry Wilcox of the Patients Rising Podcast interviewed Chief Science Policy Officer at Global Healthy Living Foundation Robert Popovian in a recent episode. He was joined by Pam Kohl, a breast cancer patient and advocate, and Kathi Luis of the Amyloidosis Foundation. Despite many promises by […]
